China YCT International Group, Inc（Symbol：CYIG）has recently released its 2013 fiscal year financial results ended March 31，2015（Please note that ‘CYIG’ has a fiscal year starting on April 1 and ending on March 31.）
■ Financial Results of FY 2014：As of March 31 2015，revenues grew by 11.4% from $34.06 million in FY 2013 to $37.94 million. The total profits increased by 8% year on year to $19.37 million.
■ During FY2014，the Huoliyuan capsules product sales was $27.09 million, which accounted for 71.47% of the total revenues, and the proportion grew by 5.4% over last fiscal year. The medicine products realized a gross profit of $13.94 million，which grew by 14.7% year on year. The production and distribution of the proprietary products has increased gradually and the proportion is also growing.
■ During FY 2014，the Company’s gross margin grew by 8% year on year to $19.37 million, and the proportion increased 2.1% over the last fiscal year. The higher sales proportion is a result of the sales of Huoliyuan capsules, which created a higher gross margin compared to the health care products.
■ As of March 31,2015，the Company invested $0.89 million into scientific research and development，accounting for 2.3% of total revenues. At present, the Company has 27 R&D specialists, all of whom are engaged in the research and development of the new technology and related products.
■ With the readings from the financial numbers，the Company has operated its businesses in a temperate and stable way. The research and development of the new products has injected vitality into the company and laid the foundation for the sustainable development of the Company.
Safe Harbor Statement
Certain statements in this press release, constitute forward-looking statements for
purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding the Company's future performance. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the periodic reports that are filed with the
Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
For more information, please contact: